Exelixis/$EXEL
Exelixis shares are trading higher after being highlighted as a well-positioned biotech stock due to strong portfolio and pipeline progress.
18 hours ago·Lightyear AI
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Ticker
$EXEL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,147
ISIN
US30161Q1040
Website
Exelixis Metrics
BasicAdvanced
$12B
20.10
$2.20
0.25
-
Price and volume
Market cap
$12B
Beta
0.25
52-week high
$49.62
52-week low
$21.82
Average daily volume
3.3M
Financial strength
Current ratio
3.499
Quick ratio
3.322
Long term debt to equity
8.781
Total debt to equity
8.781
Profitability
EBITDA (TTM)
844.281
Gross margin (TTM)
96.78%
Net profit margin (TTM)
27.99%
Operating margin (TTM)
35.43%
Effective tax rate (TTM)
23.21%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
18.05%
Return on equity (TTM)
30.22%
Valuation
Price to earnings (TTM)
20.103
Price to revenue (TTM)
5.483
Price to book
5.72
Price to tangible book (TTM)
5.89
Price to free cash flow (TTM)
16.325
Free cash flow yield (TTM)
6.13%
Free cash flow per share (TTM)
271.36%
Growth
Revenue change (TTM)
24.49%
Earnings per share change (TTM)
237.58%
3-year revenue growth (CAGR)
14.77%
10-year revenue growth (CAGR)
54.54%
3-year earnings per share growth (CAGR)
33.60%
10-year earnings per share growth (CAGR)
6.51%
What the Analysts think about Exelixis
Analyst ratings (Buy, Hold, Sell) for Exelixis stock.
Bulls say / Bears say
Exelixis reported strong financial results for Q4 2024, with total revenues reaching $567 million, driven by a 20% year-over-year increase in U.S. cabozantinib net product revenues to $515 million. (thetelegraph.com)
The company has a robust pipeline, including zanzalintinib, which analysts estimate could reach $5 billion in net U.S. sales by 2033, targeting multiple indications such as renal cell carcinoma and colorectal cancer. (finviz.com)
Exelixis authorized a $450 million share repurchase in 2024, following a $550 million repurchase in 2023, indicating strong financial health and commitment to returning value to shareholders. (markets.businessinsider.com)
Despite FDA approval of Cabometyx for advanced neuroendocrine tumors, shares fell 2.3% as analysts noted the approval was already priced into the stock. (tradingview.com)
Barclays analyst Peter Lawson maintained a Hold rating on Exelixis with a price target of $25, suggesting limited upside potential. (markets.businessinsider.com)
The company announced a corporate restructuring resulting in a 13% workforce reduction, which may indicate internal challenges or a need to streamline operations. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Exelixis Financial Performance
Revenues and expenses
Exelixis Earnings Performance
Company profitability
Exelixis News
AllArticlesVideos
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
Business Wire·2 weeks ago
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Business Wire·2 weeks ago
Product Performance, Big Money Lift Exelixis
FXEmpire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exelixis stock?
Exelixis (EXEL) has a market cap of $12B as of July 04, 2025.
What is the P/E ratio for Exelixis stock?
The price to earnings (P/E) ratio for Exelixis (EXEL) stock is 20.1 as of July 04, 2025.
Does Exelixis stock pay dividends?
No, Exelixis (EXEL) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Exelixis dividend payment date?
Exelixis (EXEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Exelixis?
Exelixis (EXEL) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.